MSP3-CRM-Vac4All/ Alhydrogel® Vaccine

Summary

Two-arm, randomized, double-blinded and controlled clinical trial to first assess the safety and tolerability of the vaccine in a Phase 1b trial and proceed to assess its efficacy against clinical malaria in young children living in highly seasonal malaria areas of Mali

Timeline

Start

2023-03-27

Primary completion

2023-12-31

Completion

2024-08-31

Drugs

Indications